[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617041":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Nicolas Collongues, MD","CONTACT","33 3.88.12.87.33","nicolas.collongues@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Centre d'Investigation Clinique - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30,32,34],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":33,"role":31,"phone":7,"phoneExt":7,"email":7},"Guillaume JOUVENOT, PhD",{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Anne KERBRAT, MD","SUB_INVESTIGATOR",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100617041","escalation-vs-induction-therapy-strategy-in-patients-with-early-onset-ms-after-age-50-100617041",false,"NCT07313462","Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50","50-CENT","Inclusion Criteria:\n\n* Patients with RRMS onset after age 50\n* Patients who started their first disease-modifying therapy within 2 years of the first symptoms\n* Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)\n* Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)\n\nExclusion Criteria:\n\n\\- Patients with early progressive MS","ALL","50 Years",{"count":49,"type":50},830,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.",[54],"Multiple Sclerosis (MS)",[54,56,57],"Escalation Therapy","Induction Therapy","2025-12-17",{"date":60,"type":61},"2026-01-02","ACTUAL",{"date":63,"type":61},"2025-02-07",{"date":65,"type":50},"2026-02",{"name":5,"class":6},1]